| Typicality: | 0.496 |
| Saliency: | 0.364 |
| currently | 10 | temporal |
| for alzheimer’s disease | 7 | other |
| in the market | 5 | location |
| drug → be in → phase iii trials | 12 |
| drug → be in → phase iii clinical trials | 12 |
| drug → undergo → phase iii clinical trials | 8 |
| drug → enter → phase iii studies | 6 |
| drug → be in → phase iii | 5 |
| drug → be in → phase 3 trials | 3 |
| negative | neutral | positive |
| 0.080 | 0.682 | 0.239 |
| Raw frequency | 46 |
| Normalized frequency | 0.364 |
| Modifier score | 0.780 |
| Perplexity | 53.020 |